Egalet researchers challenge Novo Nordisk with pills to replace needles

Two researchers who were formerly high-ranking scientists at biotech company Egalet are now running a new firm called Biograil, which is developing a speical pill to replace the need to inject drugs. The firm has recently raised USD 3.3 million for the mission.

Biograil's CEO Karsten Lindhardt (left) and technological director Nikolaj Skak have both previously held management positions at Egalet's research department. Photo: Biograil / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles